Drugs / CD19-CAR_Lenti_ALLO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06080191 | Apr 2024 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia | Bambino Gesù Hospital and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR_Lenti_ALLO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06080191 ↗ |
| Modality | Cell therapy | “fresh, donor-derived, CD19-directed-second-generation CAR T cells (alloCART)” NCT06080191 ↗ |
| Target | CD19 | “CD19-directed-second-generation CAR T cells” NCT06080191 ↗ |